January 2014 Newsletter
January 2014 Newsletter
Table of Contents
- President's Corner
- CEO Corner
- Upcoming Deadlines - IASLC Grand Rounds Webinar (Feb. 10) / ELCC Late Registration (Mar. 5)
- 2014 Member Registration is Open
- List of Events
Tony S.K. Mok, IASLC President
Early detection saves lives.
This statement is well established for multiple malignancies including breast, liver, colorectal and cervical cancers. But for lung cancer, supporting evidence for early detection of lung cancer has been lacking until the release of National Lung Screening Trial (NLST) data in 2011. Even then, lung cancer screening continues to be controversial. Doctors, health administrators and governments continue to debate the pros and cons of such massive screening project. The reasons for promoting worldwide lung cancer screening is obvious, while reasons for not doing so may include population selection bias, false positivity, risk of invasive investigation and cost. It is unlikely that we can resolve these issues and establish a global policy in the near future. Meanwhile, IASLC has the responsibility of educating doctors and patients with the existing information and promoting future research on novel detection test. The battle on early detection has just begun, and we are ready to charge.
Fred R. Hirsch, IASLC Chief Executive Officer
As we are starting a new IASLC year, we are ready to start working on our goals for 2014. The IASLC Office is currently working together with the BOD on some models how to better reach out to the community practices in the US. We are also currently exploring models for joint memberships with other cancer organizations, who have lung cancer on the agenda.
One of the new initiatives is the “IASLC Annual Report”, which we hope to present next month to our members and collaborators. Additionally, it has been a pleasure seeing the success of our new program “The Best of WCLC”, which has now been held at 10 sites (7 more to come) with very successful attendances.
Our IASLC Grand Rounds webinar series continues also with great success and several new webinars are planned for 2014. Our meeting schedule is busy. After a very successful joint meeting with AACR recently held in San Diego on “The Origin of Lung Carcinogenesis”, we are now looking forward to our annual meeting on “Targeted Therapies in Lung Cancer”, which has already exceeded expectations in terms of registrations.
We encourage our IASLC members to join our meetings (see below). In 2014 we will have regional meetings in Europe (ELCC), Latin America (LALCA), North America (Chicago Multidisciplinary Symposium in Thoracic Oncology) and in Asia (APLCC). We wish 2014 will be a successful year for all our members and we are looking forward to work with all of you in our many activities.
*NEW* IASLC Lung Cancer Grand Rounds Webinar Series - Feb. 10, 2014
A Monthly Series of Live Webinars; Ramaswamy Govindan, MD - Program Chair. 2nd Webinar: IASLC Lung Cancer Grand Rounds Series - Management of Patients with ALK Positive NSCLC Feb 10, 2014 at 8:00 pm EST - Register Now
IASLC/ESMO European Lung Cancer Conference (ELCC) - Mar. 26-29, 2014
Late Registration Deadline: Mar 5, 2014 View Details
All IASLC Meeting Information
To see the full schedule of IASLC Meetings, visit our event page.
14th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting (Feb. 19-22, 2014) Preview from Co-Chair, Paul A. Bunn, Jr., MD
The invitation-only meeting gathers the top scientists to discuss the latest advances in the treatment of lung cancer with targeted therapies. Lung Cancer therapy is undergoing considerable change and there are many exciting new therapeutic options, including exciting advances in molecular therapy, in immune therapies and in inhibition of signaling pathways. In some instances there are multiple drugs being developed for the same targets. The IASLC’s meeting on targeted therapies brings together experts on each of the targets under development to discuss ways to optimize and speed development. The discussion centers on trial design, optimization of biomarker development and maximizing efficiency of trial completion. Mechanisms of resistance, ways to overcome resistance and novel combination strategies are also discussed. A complete list of all agents under development for each target is developed. A supplement to JTO is being developed to summarize developments for each target.
The US Preventive Services Task Force Releases Recommendations for Lung Cancer Screening
In late December, the US Prevention Services Task Force (USPSTF) released recommendations for lung cancer screening of high risk individuals defined as current smokers or smokers who have quit in the last 15 years, age of 55-80 years with a smoking history on average of at least a pack of cigarettes a day for 30 years or equivalent (ex. Two packs of cigarettes a day for 15 years). It is estimated than 10 million US citizens will fall into this category, although not all will be eligible for screening due to other health issues. The recommendations are based on several studies, but the largest screening study, the National Lung Screening Study (NLST) supported by the US National Institute of Health, demonstrated a reduction in lung cancer death with 20% by low-dose CT-screening compared to chest X-ray. Read more.
AACR/IASLC Conclude Third Joint Conference on the Molecular Origins of Lung Cancer (Jan. 6-9 2014)
AACR and IASLC collaborated to produce the Third Molecular Origins of Lung Cancer Conference, January 6-9 in San Diego, California. Nearly 400 physicians, patient advocates, scientists gathered to share latest advances while promoting further collaboration. The conference was a dynamic activity covering such topics as novel therapies, prevention, early detection, patient advocacy, cancer stem cells, epigenetics, and genomics. Of particular note was a presentation by several lung cancer survivors who chronicled their paths through detection and treatment in the context of the scientific advances discussed at the conference, providing a rich background for the importance of the efforts of those in attendance. View Abstracts
50-year Anniversary of US Surgeon General's Report on Smoking
On January 17, 2014 the Surgeon General Released "The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General". The original landmark report in 1964 concluded that smoking caused lung cancer and laryngeal cancer in men. Since 1964 several additional cancer sites including oropharynx, esophagus, stomach, liver, pancreas, kidney and ureter, bladder, cervix, colorectum, and acute myeloid leukemia have been added to the list. Overall, tobacco use accounts for approximately one third of all cancer deaths annually. However, what was new in this report that is specifically relevant to clinicians involved in caring for cancer patients is the finding that tobacco smoking is causally associated with adverse outcomes in cancer patients and that quitting smoking improves the prognosis of cancer patients. According to IASLC member Dr. Graham Warren, Vice Chairman for Research in Radiation Oncology at the Medical University of South Carolina and contributing author for the 2014 Surgeon General's Report, “the findings from the 2014 Surgeon General Report warrant a paradigm shift in cancer care. The days when tobacco smoking in cancer patients could be shrugged off by clinicians as a pleasure for cancer patients to enjoy during a difficult time are long gone. In fact, for some cancer patients, the gains in survival from smoking cessation may outweigh the current standard of care cancer treatments.” The IASLC, through its Tobacco Control and Smoking Cessation Committee is engaged in providing information and encouraging policy makers to use science to address such activities as trade policy and plain packaging legislation. IASLC while beginning to add tobacco cessation topics to its education programs, is collecting links to external resources available to our members and the public. This information is now available online. The committee and IASLC staff will be adding to this content in the coming months.
Director of Communications Search
The IASLC is seeking to hire a Director of Communications to support the Association's worldwide activities and its expanding portfolio of educational and scientific products and services. Please see the job description for details on this important role.
Communications Committee Seeking Self-Nominations
Are you interested in getting more involved in IASLC? In order to meet increased communication needs, the IASLC is seeking to expand the Communications Committee. IASLC is especially interested in volunteer members who are active on social media. Please use the online form to self-nominate for the position. If you have questions, please don't hesitate to contact Chair, Anne Tsao, MD at firstname.lastname@example.org.
IASLC ALK Atlas now Available for Apple and Android
The new IASLC Atlas of ALK Testing in Lung Cancer is designed to help pathologists, laboratory scientists, and practicing physicians better understand the background, protocol, and the interpretation of results of ALK testing in patients. The Atlas is now available for downloading to iPhones, iPads and Android devices. Just like the book, the app addresses methods of testing and interpretation. With the added capability of search and extensive links the app engages the reader in the latest science. The app is available to download from the Apple iTunes App Store or the Android Google Play Store for U.S. $4.99. Published in conjunction with Editorial Rx Press and with the support of Pfizer, Inc., the IASLC Atlas of ALK Testing in Lung Cancer was first distributed to attendees at the recent IASLC World Conference on Lung Cancer in Sydney, Australia. A view only version is available on the IASLC.org website in the Research & Education/Publications section. Additional distribution channels are expected to be announced in the coming weeks.
The IASLC Multidisciplinary Approach to Thoracic Oncology is a comprehensive text with over 150 contributors. The text is being developed under the leadership of Harvey I. Pass, MD, Executive Editor and David Ball, MD, FRANZCR and Giorgio V. Scagliotti, MD, Editors. Attendees at the WCLC had an opportunity to see a pre-print of one chapter: Gender-Related Differences in Lung Cancer written by Silvia Novello, MD, PhD, Laura P. Stabile, PhD and Jill M. Siegfried, PhD. The book will be available in print and electronic versions at the ASCO meeting next May. Stay tuned for more announcements in the coming months.
IASLC Launches 40th Anniversary Celebration in Sydney
WCLC 2013 delegates all received a copy of the Progress in Lung Cancer booklet. ALL IASLC Members who receive the print version of the JTO received a 40th Anniversary DVD which features experts telling the story of lung cancer over the past 40 years! All IASLC members and other interested individuals may also view the videos and timeline from each decade: Watch the 40th Anniversary videos online. You can also now Download the IASLC Progress in Lung Cancer Monograph. Support for this project from Lilly Oncology and Company is gratefully acknowledged.
IASLC 2014 Online Member Registration is Open - 3-year Membership Now Available
All Members will begin receiving their member renewal notices via email. Please note that IASLC dues for Regular Members from developed countries have increased to $250.00, while dues for Developing Country and Allied Health Professional Members remain $50.00.
There are new options for each member category and Regular Members from developed countries may "lock-in" the previous member rates, and save $150.00 over three years by selecting the 3-year Membership option ($600.00).
We encourage all members to renew early so we can ensure you have no interruption of benefits or JTO delivery and online access. Please review the single-year and multi-year options available to you!
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.
WCLC Virtual Library
December 12 2016 - January 27 2017Multiple Locations Around the World
Multidisciplinary Hands-On Live Learning: Molecular Testing and Personalized Therapy in Lung Cancer - San FranciscoJanuary 7 2017San Francisco, CA
February 22 - 25 2017Santa Monica, CA